27 July 2022>: Meta-Analysis
The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
Mengjie Li 1234ABCDEFG* , Guangzhi Ma 1ABCDEF* , Xuebing Li 2ACFG* , Qinghua Zhou 12ACFG*DOI: 10.12659/MSM.936898
Med Sci Monit 2022; 28:e936898
Table 1 Characteristics of the included articles.
Author | Country | Median age | N (F/M) | Clinical stage | Method | Antibody | HR estimation | Cut-off | Periostin (H/L) | Quality score |
---|---|---|---|---|---|---|---|---|---|---|
Iwamoto 2021 []25 | Japan | 65 | 73 (34/39) | I–IIIA | IHC | MM | HR+Cl | Score ≥4 | 34/39 | 7 |
Ratajczak-Wielgomas 2020 []24 | Poland | NA | NA | I–IV | IHC | RP | HR+Cl | Score >7 | 360/340 | 8 |
Okazaki 2018 []19 | Japan | NA | 189 (83/106) | I–III | IHC | RP | HR+Cl | Score ≥2 | 83/106 | 8 |
Murakami 2018 []18 | Japan | 68 | 184 (83/101) | I–III | IHC | MM | HR+Cl | Score >43265.5 | 92/92 | 8 |
Zhang 2017 []20 | China | NA | 122 (34/88) | III–IV | ELISA | MM | HR+Cl | 435.04 ng/mL | NA | 7 |
Xu 2017 []21 | China | 56.6 | 296 (116/180) | I–IV | ELISA | kit* | HR+Cl | 30.87 ng/mL | NA | 7 |
Nitsche 2016 []26 | Germany | NA | 93 (37/56) | I–IV | IHC | RP | HR+Cl | Median value | 47/46 | 7 |
Hong 2013 []22 | China | 57.132 | 49 (11/38) | I–IV | Western Blot | RP | HR+Cl | NA | 22/27 | 7 |
Takanami 2008 []27 | Japan | 65.5 | 88 (25/63) | I–IIIA | IHC | MM | HR+Cl | Score ≥+ | 37/51 | 8 |
Soltermann 2008 []28 | Switzerl-and | NA | 516 (149/367) | I–IV | IHC | RP | HR+Cl | Score >3 | 160/356 | 7 |
Sasaki 2001 []23 | Japan | 64.5 | 102 (24/78) | I–IV | RT-PCR | NA | Survival curves | Ratio >2.0# | 50/52 | 7 |
Sasaki 2001 []16 | Japan | 63 | 92 (19/73) | I–IIIB | Chemilum-inescence | 5H8, E17** | Survival curves | 962 ng/mL | 46/46 | 7 |
CI – confidence interval; F – female; H – high; HR – hazard ratio; IHC – immunohistochemistry; L – low; M – male; MM – mouse monoclonal anti-periostin antibody; MVD – microvessel density; N – number of patients; NA – not available; RP – rabbit polyclonal anti-periostin antibody; * kit – commercial periostin ELISA Ready-SET-Go kit; ** 5H8=monoclonal antibody and E17=polyclonal antibody; # ratio – tumor/normal ratio. |